Is Aligos Therapeutics, Inc. overvalued or undervalued?

As of 5 August 2021, the valuation grade for Aligos Therapeutics, Inc. moved from does not qualify to risky, indicating increased concerns about its financial health. The company appears to be overvalued given its current metrics, particularly with a Price to Book Value of 0.38 and an EV to EBITDA ratio of 1.07, which suggests that the market may be pricing in excessive optimism despite the company's losses. In comparison, peers like Checkpoint Therapeutics, Inc. and CASI Pharmaceuticals, Inc. have significantly worse valuation ratios, with EV to EBITDA ratios of -5.9896 and -1.1923, respectively, highlighting that Aligos is not the worst performer in its group despite its challenges.
The stock has underperformed against the S&P 500, with a year-to-date return of -74.92% compared to the index's 12.22%. This stark contrast reinforces the notion that Aligos Therapeutics is currently overvalued, as the market sentiment does not align with the company's financial performance and outlook.